Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Revenue (2022 - 2025)

Stoke Therapeutics has reported Revenue over the past 4 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Revenue at $1.4 million for Q4 2025, down 93.8% from a year ago — trailing twelve months through Dec 2025 was $184.4 million (up 404.5% YoY), and the annual figure for FY2025 was $184.4 million, up 404.5%.
  • Revenue for Q4 2025 was $1.4 million at Stoke Therapeutics, down from $10.6 million in the prior quarter.
  • Over the last five years, Revenue for STOK hit a ceiling of $158.6 million in Q1 2025 and a floor of $1.4 million in Q4 2025.
  • Median Revenue over the past 4 years was $3.8 million (2023), compared with a mean of $15.4 million.
  • Peak annual rise in Revenue hit 3661.12% in 2025, while the deepest fall reached 93.8% in 2025.
  • Stoke Therapeutics' Revenue stood at $3.3 million in 2022, then decreased by 14.26% to $2.8 million in 2023, then skyrocketed by 707.07% to $22.6 million in 2024, then plummeted by 93.8% to $1.4 million in 2025.
  • The last three reported values for Revenue were $1.4 million (Q4 2025), $10.6 million (Q3 2025), and $13.8 million (Q2 2025) per Business Quant data.